Bone Biologics annual return on equity
2022
2023
2024
2025
Bone Biologics Return on Equity (ROE) Growth & History (BBLG)
Bone Biologics's return on equity was −70.17% for fiscal 2025.
View full Bone Biologics company overviewBone Biologics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −70.17% | +58.54 pp |
| 2024 | 2024-12-31 | −128.71% | +73.43 pp |
| 2023 | 2023-12-31 | −202.15% | −178.44 pp |
| 2022 | 2022-12-31 | −23.71% | — |
Bone Biologics quarterly return on equity
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −18.00% | −2.43 pp |
| Q1 2026 | 2026-03-31 | −15.25% | +16.56 pp |
| Q4 2025 | 2025-12-31 | −12.02% | +29.81 pp |
| Q3 2025 | 2025-09-30 | −10.57% | +17.51 pp |
| Q2 2025 | 2025-06-30 | −15.58% | +8.23 pp |
| Q1 2025 | 2025-03-31 | −31.81% | −5.50 pp |
| Q4 2024 | 2024-12-31 | −41.83% | +4.44 pp |
| Q3 2024 | 2024-09-30 | −28.08% | +12.39 pp |
| Q2 2024 | 2024-06-30 | −23.81% | +17.99 pp |
| Q1 2024 | 2024-03-31 | −26.32% | +58.78 pp |
| Q4 2023 | 2023-12-31 | −46.27% | −63.54 pp |
| Q3 2023 | 2023-09-30 | −40.47% | −16.06 pp |
| Q2 2023 | 2023-06-30 | −41.80% | −33.73 pp |
| Q1 2023 | 2023-03-31 | −85.09% | −74.16 pp |
| Q4 2022 | 2022-12-31 | 17.27% | — |
| Q3 2022 | 2022-09-30 | −24.41% | — |
| Q2 2022 | 2022-06-30 | −8.07% | — |
| Q1 2022 | 2022-03-31 | −10.93% | — |
Bone Biologics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Bone Biologics's return on equity decreased from −23.71% to −70.17%, a change of −46.46 percentage points. The latest reported quarter, Q2 2026, shows −18.00%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bone Biologics source filings ↗